Company profile: Pherin
1.1 - Company Overview
Company description
- Provider of clinical-stage investigational drugs for psychiatric and neurological disorders, particularly anxiety and depression, developing pherines (a new class of drugs) and an oral antagonist targeting the glycine site of the N-methyl-D-aspartate receptor (NMDAR). Privately held.
Products and services
- Oral antagonist of the glycine site of the N-methyl-D-aspartate receptor (NMDAR): Investigational oral, receptor-targeted product that targets the NMDAR glycine site, intended for treating psychiatric and neurological disorders
- Pherines: Clinical-stage investigational class engineered to treat psychiatric and neurological disorders, particularly anxiety and depression, representing a new drug category
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Pherin
Embrella Cardiovascular
HQ: United States
Website
- Description: Provider of a medical device system to enhance embolic cerebral protection, helping interventionalists reduce the frequency of embolic strokes during cardiovascular procedures; based in Malvern, Pennsylvania.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Embrella Cardiovascular company profile →
Convergence Pharmaceuticals
HQ: United Kingdom
Website
- Description: Provider of novel analgesics for the treatment of chronic pain. An independent biotechnology company focused on developing therapies with potentially commercially attractive efficacy, responder-rate, and side effect profiles. Formed in October 2010 following the acquisition of certain neuroscience clinical assets from GlaxoSmithKline (GSK).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Convergence Pharmaceuticals company profile →
Carbylan
HQ: United States
Website
- Description: Provider of products and services; specific offerings not available. Founded in 2004.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Carbylan company profile →
Remedy Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage small molecule drug therapies for acute central nervous system disorders, developing treatments that target NCCa-ATP channels in traumatic brain injury, stroke, and spinal cord injury, including RP-1127, an intravenous glyburide inhibitor acting through type-1 sulfonylurea antagonism.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Remedy Pharmaceuticals company profile →
Sio Gene Therapies
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sio Gene Therapies company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Pherin
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Pherin
2.2 - Growth funds investing in similar companies to Pherin
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Pherin
4.2 - Public trading comparable groups for Pherin
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →